Holen Sie sich die Stockscreener-App
7.89
1.13%
-0.09
Handel nachbörslich:
7.91
0.02
+0.25%
Schlusskurs vom Vortag:
$7.98
Offen:
$7.99
24-Stunden-Volumen:
2.60M
Relative Volume:
0.57
Marktkapitalisierung:
$2.43B
Einnahmen:
$493.67M
Nettoeinkommen (Verlust:
$-104.69M
KGV:
-23.21
EPS:
-0.34
Netto-Cashflow:
$-31.51M
1W Leistung:
+0.13%
1M Leistung:
+16.72%
6M Leistung:
-10.95%
1J Leistung:
-31.45%
1-Tages-Spanne:
$7.8002
$7.99
1-Wochen-Bereich:
$7.69
$8.19
52-Wochen-Spanne:
$5.51
$12.65
Amicus Therapeutics Inc Stock (FOLD) Company Profile
Firmenname
Amicus Therapeutics Inc
Sektor
Branche
Telefon
(609) 662-2000
Adresse
47 HULFISH STREET, PRINCETON, NJ
Vergleichen Sie FOLD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FOLD
Amicus Therapeutics Inc
|
7.89 | 2.46B | 493.67M | -104.69M | -31.51M | -0.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.48 | 101.34B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
482.13 | 59.64B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.53 | 59.19B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
767.00 | 47.00B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
351.13 | 38.12B | 3.81B | -644.79M | -669.77M | -6.24 |
Amicus Therapeutics Inc Stock (FOLD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-13 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-09-06 | Eingeleitet | Jefferies | Buy |
| 2024-05-30 | Eingeleitet | Wells Fargo | Overweight |
| 2024-05-14 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-12-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-04-13 | Fortgesetzt | Goldman | Neutral |
| 2022-01-14 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-15 | Hochstufung | Stifel | Hold → Buy |
| 2021-09-30 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-07-19 | Fortgesetzt | BTIG Research | Buy |
| 2021-05-27 | Eingeleitet | Needham | Hold |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-04-14 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2021-03-02 | Eingeleitet | Stifel | Hold |
| 2021-02-12 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-12 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-12-28 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2020-12-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-11-11 | Eingeleitet | Berenberg | Hold |
| 2020-06-17 | Eingeleitet | BTIG Research | Buy |
| 2020-02-04 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2019-11-12 | Bestätigt | H.C. Wainwright | Buy |
| 2019-06-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-06-05 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2019-04-05 | Eingeleitet | Janney | Buy |
| 2019-01-30 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-10-29 | Eingeleitet | Citigroup | Neutral |
| 2018-08-17 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2017-10-06 | Fortgesetzt | Goldman | Neutral |
| 2017-09-13 | Bestätigt | Chardan Capital Markets | Buy |
| 2017-08-10 | Bestätigt | Chardan Capital Markets | Buy |
| 2017-01-24 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2016-05-18 | Eingeleitet | BofA/Merrill | Buy |
| 2016-04-14 | Eingeleitet | Robert W. Baird | Neutral |
| 2016-04-12 | Bestätigt | Chardan Capital Markets | Buy |
| 2015-09-16 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2015-06-16 | Bestätigt | Chardan Capital Markets | Buy |
Alle ansehen
Amicus Therapeutics Inc Aktie (FOLD) Neueste Nachrichten
Banque Transatlantique SA Acquires Shares of 166,491 Amicus Therapeutics, Inc. $FOLD - MarketBeat
Amicus Therapeutics Presents Long-Term Efficacy Data for Cipaglucosidase Alfa and Miglustat in Late-Onset Pompe Disease at ICIEM 2025 - Quiver Quantitative
New 4-Year Data for Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Presented at ICIEM - GlobeNewswire
Breakthrough 4-Year Results: Amicus Pompe Disease Treatment Maintains Muscle Function in Long-term Study - Stock Titan
Parkman Healthcare Partners LLC Decreases Stock Holdings in Amicus Therapeutics, Inc. $FOLD - MarketBeat
Vestal Point Capital LP Grows Stake in Amicus Therapeutics, Inc. $FOLD - MarketBeat
Dark Forest Capital Management LP Raises Stake in Amicus Therapeutics, Inc. $FOLD - MarketBeat
Palo Alto Investors LP Sells 317,477 Shares of Amicus Therapeutics, Inc. $FOLD - MarketBeat
Amicus Therapeutics, Inc. $FOLD Stock Holdings Decreased by Trexquant Investment LP - MarketBeat
683 Capital Management LLC Acquires New Holdings in Amicus Therapeutics, Inc. $FOLD - MarketBeat
Amicus Therapeutics, Inc. $FOLD is Redmile Group LLC's 3rd Largest Position - MarketBeat
552,025 Shares in Amicus Therapeutics, Inc. $FOLD Purchased by Cubist Systematic Strategies LLC - MarketBeat
PDT Partners LLC Buys 388,817 Shares of Amicus Therapeutics, Inc. $FOLD - MarketBeat
Rafferty Asset Management LLC Trims Stock Position in Amicus Therapeutics, Inc. $FOLD - MarketBeat
Can Amicus Therapeutics Inc. outperform under higher oil pricesPrice Action & Expert-Curated Trade Recommendations - خودرو بانک
Ranking Amicus Therapeutics Inc. among high performing stocks via toolsWeekly Investment Recap & Advanced Technical Signal Analysis - Newser
What analysts say about Amicus Therapeutics Inc. stockWeekly Profit Recap & Verified Chart Pattern Trade Signals - خودرو بانک
Is Amicus Therapeutics Inc. a candidate for recovery playPortfolio Return Summary & AI Driven Stock Reports - Newser
Can a trend reversal in Amicus Therapeutics Inc. lead to recoveryJuly 2025 Update & Safe Capital Allocation Plans - Newser
Amicus Therapeutics Inc. stock momentum explained2025 Market Sentiment & Growth Focused Investment Plans - Newser
How to read the order book for Amicus Therapeutics Inc.2025 Stock Rankings & Daily Market Momentum Tracking - Newser
Is this a good reentry point in Amicus Therapeutics Inc.July 2025 Final Week & High Accuracy Trade Signal Alerts - Newser
Using economic indicators to assess Amicus Therapeutics Inc. potentialJuly 2025 Recap & Pattern Based Trade Signal System - Newser
Evaluating Amicus Therapeutics Inc. with trendline analysisMarket Performance Recap & Reliable Price Breakout Alerts - Newser
Is Amicus Therapeutics Inc. reversing from oversold territory2025 Macro Impact & Verified Momentum Watchlists - Newser
Quantitative breakdown of Amicus Therapeutics Inc. recent moveMarket Rally & Scalable Portfolio Growth Methods - Newser
Kodai Capital Management LP Purchases New Stake in Amicus Therapeutics, Inc. $FOLD - MarketBeat
Using AI based signals to follow Amicus Therapeutics Inc.Portfolio Performance Report & AI Forecasted Entry/Exit Points - Newser
Wall Street Zen Downgrades Amicus Therapeutics (NASDAQ:FOLD) to Hold - MarketBeat
Should you hold or exit Amicus Therapeutics Inc. now2025 Volatility Report & Short-Term Trading Alerts - Newser
Russell Investments Group Ltd. Increases Stock Holdings in Amicus Therapeutics, Inc. $FOLD - MarketBeat
Real time social sentiment graph for Amicus Therapeutics Inc.2025 Macro Impact & Safe Entry Momentum Stock Tips - Newser
Reversal indicators forming on Amicus Therapeutics Inc. stockJuly 2025 Drop Watch & Reliable Price Breakout Alerts - Newser
Using Python tools to backtest Amicus Therapeutics Inc. strategiesCEO Change & Reliable Price Action Trade Plans - Newser
Earnings visualization tools for Amicus Therapeutics Inc.2025 AllTime Highs & Verified Short-Term Plans - Newser
How to build a custom watchlist for Amicus Therapeutics Inc.2025 Retail Activity & Free Weekly Chart Analysis and Trade Guides - Newser
Applying Wyckoff theory to Amicus Therapeutics Inc. stockJuly 2025 Levels & Safe Capital Investment Plans - Newser
Is Amicus Therapeutics Inc. stock a buy or sell getLinesFromResByArray error: size == 0 - 머스트 뉴스
Has Amicus Therapeutics Inc. found a price floorMarket Risk Analysis & Low Risk High Reward Trade Ideas - Newser
What makes Amicus Therapeutics Inc. stock price move sharplyJuly 2025 Intraday Action & Precise Entry and Exit Recommendations - Newser
Analyzing Amicus Therapeutics Inc. with risk reward ratio chartsWeekly Market Outlook & Target Return Focused Stock Picks - Newser
Price Channel Expanding on Amicus Therapeutics Inc.’s Chart getLinesFromResByArray error: size == 0 - thegnnews.com
Finanzdaten der Amicus Therapeutics Inc-Aktie (FOLD)
Umsatz
Nettogewinn
Free Cashflow
ENV
Amicus Therapeutics Inc-Aktie (FOLD) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Campbell Bradley L | President and CEO |
Feb 19 '25 |
Sale |
10.00 |
400 |
4,000 |
1,150,657 |
1.96%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):